NCT06440980View on ClinicalTrials.gov

A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight

PHASE1CompletedINTERVENTIONAL
Enrollment

533

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

June 2, 2025

Study Completion Date

June 2, 2025

Conditions
HealthyObeseOverweightObesity
Interventions
DRUG

Orforglipron

Administered orally

Trial Locations (7)

32117

Fortrea Clinical Research Unit, Daytona Beach

53704

Fortrea Clinical Research Unit, Madison

65802

QPS, Springfield

66212

Altasciences Company Inc., Overland Park

75247

Fortrea Clinical Research Unit, Dallas

90720

Collaborative Neuroscience Research, LLC, Los Alamitos

92801

Anaheim Clinical Trials, LLC, Anaheim

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT06440980 - A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight | Biotech Hunter | Biotech Hunter